Glenmark Pharmaceuticals Performance
- Today's Low
- ₹2,148
- Today's High
- ₹2,195
- 52 Week Low
- ₹1,680
- 52 Week High
- ₹2,474
- Open Price₹2,181
- Previous Close₹2,181
- Volume348,933
- 50 DMA₹2,216.86
- 100 DMA₹2,176.81
- 200 DMA₹2,071.36
Glenmark Pharmaceuticals Chart
Investment Returns
- Over 1 Month -7.81%
- Over 3 Month -0.65%
- Over 6 Month + 6.65%
- Over 1 Year + 25.47%
Smart Investing Starts Here Start SIP with Glenmark Pharmaceuticals for Steady Growth!
Glenmark Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 44.6
- PEG Ratio
- 1.5
- Market Cap Cr
- 60,797
- P/B Ratio
- 5.8
- Average True Range
- 63.65
- EPS
- 104.59
- Dividend Yield
- 0.2
- MACD Signal
- -30.76
- RSI
- 42.48
- MFI
- 45.41
Latest Stock News Updates
Glenmark Pharmaceuticals on Thursday said it has received final approval from the US health regulator for its generic version of progesterone vaginal inserts used in fertility treatments. The approval by the US Food and Drug Administration (USFDA) is for progesterone vaginal inserts of strength 100 mg, Glenmark Pharmaceuticals Ltd said in a regulatory filing. It has been determined by the USFDA to be bioequivalent and therapeutically equivalent to the reference listed drug, Endometrin vaginal inserts, 100 mg of Ferring Pharmaceuticals Inc, it added. Glenmark's progesterone vaginal inserts 100 mg will be distributed in the US by Glenmark Pharmaceuticals Inc, USA, the company said. "This approval for Progesterone Vaginal Inserts, 100 mg marks an important addition to our business and reinforces our focus on addressing patient needs in women's healthcare," Glenmark President & Business Head, North America, Marc Kikuchi said. Citing IQVIA sales data for the 12 months ended February ..
- Business Standard
- 2 months 2 weeks ago
Glenmark Pharmaceuticals on Friday said its US-based unit is gearing up to introduce a generic sodium phosphates injection in the American market. The Mumbai-based drug firm said its product is therapeutically equivalent to Hosira Inc's reference listed drug. Glenmark will begin distribution of the injection in the US market in April 2026, it said in a regulatory filing. According to IQVIA, sales data for the 12-month period ending December 2025, the Sodium Phosphates Injection USP single-dose vials saw annual sales of around USD 66.8 million. Shares of the company were trading 0.82 per cent up at Rs 2,144.50 apiece on BSE.
- Business Standard
- 3 months 3 weeks ago
Glenmark Pharmaceuticals Financials
Glenmark Pharmaceuticals Technicals
EMA & SMA
- Bearish Moving Average 13
- Bullish Moving Average 3
- 20 Day
- ₹2,195.30
- 50 Day
- ₹2,216.90
- 100 Day
- ₹2,176.80
- 200 Day
- ₹2,071.40
Resistance and Support
- R3 2,230.87
- R2 2,212.93
- R1 2,183.67
- S1 2,136.47
- S2 2,118.53
- S3 2,089.27
Glenmark Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends
Glenmark Pharmaceuticals F&O
About Glenmark Pharmaceuticals
- NSE Symbol
- GLENMARK
- BSE Symbol
- 532296
- Chairman & Managing Director
- Mr. Glenn Saldanha
- ISIN
- INE935A01035
Similar Stocks to Glenmark Pharmaceuticals
Popular Stocks
Glenmark Pharmaceuticals FAQs
Glenmark Pharmaceuticals share price is ₹2,154 As on 27 June, 2026 | 03:02
The Market Cap of Glenmark Pharmaceuticals is ₹60797.3 Cr As on 27 June, 2026 | 03:02
The P/E ratio of Glenmark Pharmaceuticals is 44.6 As on 27 June, 2026 | 03:02
The PB ratio of Glenmark Pharmaceuticals is 5.8 As on 27 June, 2026 | 03:02
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.